Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNK333 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| DNK333 5 mg | EXPERIMENTAL | - |
| Placebo to DNK333 5mg | PLACEBO_COMPARATOR | - |
| DNK333 25 mg | EXPERIMENTAL | - |
| Placebo to DNK333 25 mg | PLACEBO_COMPARATOR | - |
| DNK333 100 mg | EXPERIMENTAL | - |
| Placebo to DNK333 100 mg | PLACEBO_COMPARATOR | - |
| Betamethasone 4 mg | ACTIVE_COMPARATOR | - |
| DNK333 1 mg | EXPERIMENTAL | - |
| placebo 1mg | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNK333 5 mg | DRUG | 5 mg oral |
| Placebo to 5 mg | DRUG | 5 mg placebo oral |
| DNK333 25 mg | DRUG | 25 mg oral |
| Placebo to 25 mg | DRUG | 25 mg placebo oral |
| DNK333 100 mg | DRUG | 100 mg oral |
| Placebo to 100 mg | DRUG | 100 mg placebo oral |
| Betamethasone 4 mg | DRUG | 4 mg oral |
| DNK333 1mg | DRUG | 1 mg oral |
| Placebo to 1mg | DRUG | 1 mg placebo oral |
| DNK333 | DRUG | DNK333 25mg b.i.d. given orally for 4 weeks |
| Placebo | DRUG | Matching placebo |
Inclusion Criteria: * Male and female atopic dermatitis patients,18 to 60 years of age inclusive, who fulfill the following criteria: * Requirement of systemic therapy * Itch VAS score higher than 50 mm * EASI score higher than 8 Exclusion Criteria: * Women of child-bearing potential who are not ...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 1 | PHASE3 | Eluxadoline |
| Ardelyx, Inc. | ARDX | 2 | PHASE3 | Tenapanor |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Eli Lilly and Company | LLY | 2 | PHASE2 | LY3537031 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE2 | Camlipixant |
DNK333 is an investigational small molecule developed by Novartis AG for gastrointestinal and dermatologic conditions. It has been studied in Phase 2 clinical trials for irritable bowel syndrome, diarrhea-predominant irritable bowel syndrome (IBS-D), and pruritus in patients with atopic dermatitis. It is not approved and remains in clinical development.
DNK333 was studied as a treatment for diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women. Phase 2 trials evaluated its efficacy, safety, and tolerability in this population. The trials have been completed, and the drug is not approved for IBS-D or any other indication.
DNK333 targets TACR1, also known as the neurokinin 1 (NK1) receptor. It acts as a TACR1 antagonist, meaning it blocks the activity of this receptor. TACR1 antagonism is the mechanism explored in its clinical development for IBS-D and pruritus in atopic dermatitis.
DNK333 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 2 clinical trials evaluating DNK333 in irritable bowel syndrome and pruritus in atopic dermatitis.
DNK333 is in Phase 2. All of its clinical trials have been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
DNK333 has been evaluated in three completed Phase 2 trials: NCT01033097 in atopic dermatitis pruritus, NCT00699166 in IBS-D, and NCT00394173 in IBS-D. All were randomized, double-blind, and placebo-controlled, enrolling adults aged 18 and older.